Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 48Rituximab 32fludarabine 29Doxorubicin 14Specimen Handling 13Magnetic Resonance Spectroscopy 13Vincristine 12Prednisone 12pirtobrutinib 11fludarabine phosphate 10Etoposide 10Bendamustine Hydrochloride 10Immunotherapy, Adoptive 9obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7pembrolizumab 7glofitamab 7zanubrutinib 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Inotuzumab Ozogamicin × 1 year × Clear all
NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
23 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡